Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 101

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 101
---
, except as may be required under applicable securities laws. 24 Risk Factors In addition to the other information contained in (or incorporated by reference into) this proxy statement / prospectus, including the matters addressed under the heading “ Forward -Looking Statements,” you should carefully consider the following risk factors in deciding how to vote on the proposals presented in this proxy statement / prospectus. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on the Company business, reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of the Company Shares could decline, and you could lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this proxy statement / prospectus to the Company business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, the business, reputation, financial condition, results of operations, revenue and future prospects of the Company. Risks Related to Our Business and Strategy Our growth and success depend on our ability to develop current and new products to grow our presence in the personal genetics market. Our success in the personal genetics market depends on our ability to grow our market position, develop new services, provide customers with high -qualitytest reports quickly and at a lower price than our competitors, and achieve sufficient test and related services volume to realize economies of scale. To do this, we must significantly scale our infrastructure, including our testing capacity and information systems, expand our commercial operations, customer service, billing and systems processes, and enhance our internal quality assurance program. We must also innovate and adequately invest in artificial intelligence development as well as new technologies to keep pace with the rapid rate of change in our markets and meet customer needs. Our continued growth also depends on our ability to successfully develop and introduce new products and services on a timely basis, as well as our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. We need to be able to differentiate our products from well -established, large competitors in the market and start to prepare products for international markets in multiple aspects. If we are unable to do so, our operations may be adversely affected. For at least the next twelve months, our ability to generate revenues will depend substantially on the commercial success of our tests and services. There can be no assurance that we will develop or commercialize any other products or services that will generate significant revenue, or